Literature DB >> 658622

Restoration of the acute insulin response by sodium salicylate. A glucose dose-related phenomenon.

M Chen, R P Robertson.   

Abstract

Adult-onset diabetics have markedly diminished or absent acute insulin responses to glucose that can be partially restored by sodium salicylate infusion. To determine whether this restoration of the acute insulin response is glucose dose dependent and whether complete restoration can be achieved, adult-onset diabetics with a mean fasting plasma glucose value of 216 +/- 20 mg. per deciliter (x +/- S.E.) were stimulated with various doses of intravenous glucose. Restoration occurred in a glucose dose-dependent manner. Complete restoration could not be achieved with the maximal tolerable glucose dose (80 gm.). Second phase insulin secretion also improved in a glucose dose-dependent manner. These findings are compatible with the hypothesis that defective insulin secretion in adult-onset, hyperglycemic diabetics is not due to absolute deficiency of insulin but may be a result of defective recognition of glucose signals by pancreatic B-cells--a defect that can be partially reversed by sodium salicylate.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 658622     DOI: 10.2337/diab.27.7.750

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  13 in total

Review 1.  Therapeutic approaches to target inflammation in type 2 diabetes.

Authors:  Allison B Goldfine; Vivian Fonseca; Steven E Shoelson
Journal:  Clin Chem       Date:  2010-11-22       Impact factor: 8.327

2.  Inflammatory signaling: another drug target to improve glycemic control in type 2 diabetes.

Authors:  Barry J Goldstein
Journal:  Clin Transl Sci       Date:  2008-05       Impact factor: 4.689

3.  Effect of naproxen on glucose metabolism and tolbutamide kinetics and dynamics in maturity onset diabetics.

Authors:  B Whiting; R L Williams; M Lorenzi; J C Varady; D S Robins
Journal:  Br J Clin Pharmacol       Date:  1981-03       Impact factor: 4.335

4.  Sodium salicylate restores the impaired insulin response to glucose and improves glucose tolerance in heroin addicts.

Authors:  D Giugliano; A Quatraro; G Consoli; A Stante; V Simeone; A Ceriello; G Paolisso; R Torella
Journal:  Acta Diabetol Lat       Date:  1987 Jul-Sep

5.  IKKβ inhibition prevents fat-induced beta cell dysfunction in vitro and in vivo in rodents.

Authors:  Aleksandar Ivovic; Andrei I Oprescu; Khajag Koulajian; Yusaku Mori; Judith A Eversley; Liling Zhang; Rodolfo Nino-Fong; Gary F Lewis; Marc Y Donath; Michael Karin; Michael B Wheeler; Jan Ehses; Allen Volchuk; Catherine B Chan; Adria Giacca
Journal:  Diabetologia       Date:  2017-07-20       Impact factor: 10.122

Review 6.  A meta-analysis of salicylates for type 2 diabetes mellitus.

Authors:  Fang Fang; Yu Lu; De-Lin Ma; Ting-Ting Du; Shi-Ying Shao; Xue-Feng Yu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-02-08

7.  Effect of salicylate poisoning on insulin secretion. Studies on its mechanism of action.

Authors:  M Arata; L Karabatas; M E Fernández; J C Cresto; E Astolfi; J C Basabe
Journal:  Acta Diabetol Lat       Date:  1983 Jul-Sep

8.  Long-term administration of acetylsalicylic acid in impaired glucose tolerance in addition to the diet: effects and limits.

Authors:  F Caviezel; A G Cattaneo; G Pozza
Journal:  Acta Diabetol Lat       Date:  1981 Jul-Sep

9.  Failure of indomethacin to affect arginine-induced C-peptide and glucagon release in insulin-treated diabetics. Major role of residual B cell function in conditioning the magnitude of the blood glucose rise after intravenous arginine.

Authors:  A S Luyckx; E Mendoza; P J Lefebvre
Journal:  Diabetologia       Date:  1981-10       Impact factor: 10.122

10.  Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes.

Authors:  Allison B Goldfine; Robert Silver; Waleed Aldhahi; Dongsheng Cai; Elizabeth Tatro; Jongsoon Lee; Steven E Shoelson
Journal:  Clin Transl Sci       Date:  2008-05       Impact factor: 4.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.